



DRUG QUANTITY MANAGEMENT POLICY – PER RX

POLICY: Oncology – Copiktra Drug Quantity Management Policy – Per Rx

- Copiktra® (duvelisib capsules – Secura Bio)

REVIEW DATE: 09/04/2025

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Copiktra, a phosphatidylinositol 3-kinase (PI3K) inhibitor, is indicated for the treatment of relapsed or refractory **chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)** after at least two prior therapies in adults.¹

Dosing

The recommended dose of Copiktra is 25 mg twice daily (BID) in a 28-day cycle.¹ Swallow capsules whole, do not open, break, or chew. To manage adverse events, the dose of Copiktra may need to be reduced to 15 mg BID or Copiktra may need to be discontinued (details provided in the prescribing information.) The dose of Copiktra should also be reduced to 15 mg BID if it will be co-administered with a strong cytochrome P450 (CYP)3A4 inhibitor. Patients taking Copiktra should avoid taking a strong CYP3A4 inducer. If Copiktra will be used concomitantly with a moderate CYP3A4 inducer, the dose should be increased to 40 mg BID (if the original dose was 25 mg BID) or 25 mg BID (if the original dose was 15 mg BID).

Availability

Copiktra is available as a 15 mg and 25 mg capsule in cartons containing 56 capsules each (two 28-count blister packs).

Off-Label Dosing

Copiktra is also used off-label for the treatment of T-cell lymphoma.² The NCCN guidelines on T-cell lymphoma (version 02.2025 – May 28, 2025) recommend Copiktra as “preferred” initial palliative intent therapy or second-line or and subsequent therapy for peripheral T-cell lymphoma; as second-line and subsequent therapy for relapsed/refractory disease for breast implant-associated anaplastic large cell lymphoma; and for hepatosplenic T-cell lymphoma as a single agent for refractory disease after two first-line therapy regimens (all category 2A). According to the guidelines, in the phase II study, the preferred dosing regimen of Copiktra was 75 mg BID for 2 cycles followed by 25 mg BID for long-term disease control.

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Copiktra. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below. “One-time” approvals are provided for 30 days in duration.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per Rx	Home Delivery Maximum Quantity per Rx
Copiktra® (duvelisib capsules)	15 mg capsules	56 capsules	168 capsules
	25 mg capsules	56 capsules	168 capsules

EXCEPTIONS TO THE QUANTITY LIMITS LISTED ABOVE ARE COVERED AS MEDICALLY NECESSARY WHEN THE FOLLOWING CRITERIA ARE MET. ANY OTHER EXCEPTION IS CONSIDERED NOT MEDICALLY NECESSARY.

CRITERIA

Copiktra 15 mg capsules

No overrides recommended.

Copiktra 25 mg capsules

1. If the patient is initiating treatment for T-cell lymphoma or requires additional induction dosing for T-cell lymphoma, approve 168 capsules per dispensing at retail and a one-time override for 392 capsules at home delivery.

Note: The approval duration at retail is 56 days to accommodate two 28-day dosing cycles. At home delivery, 392 capsules is a quantity sufficient for 2 cycles at 75 mg twice daily (BID), followed by 25 mg BID.

REFERENCES

1. Copiktra® capsules [prescribing information]. Las Vegas, NV: Secura Bio; July 2024.
2. The NCCN T-Cell Lymphomas Clinical Practice Guidelines in Oncology (version 2.2025 – May 28, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on August 7, 2025.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	New policy was created to provide overrides to existing quantity limits.	09/11/2024
Annual Revision	The Policy Statement was updated to note that “one-time” approvals are provided for 30 days in duration.	09/04/2025

"CIGNA COMPANIES" REFERS TO OPERATING SUBSIDIARIES OF THE CIGNA GROUP. ALL PRODUCTS AND SERVICES ARE PROVIDED EXCLUSIVELY BY OR THROUGH SUCH OPERATING SUBSIDIARIES, INCLUDING CIGNA HEALTH AND LIFE INSURANCE COMPANY, CONNECTICUT GENERAL LIFE INSURANCE COMPANY, EVERNORTH BEHAVIORAL HEALTH, INC., CIGNA HEALTH MANAGEMENT, INC., AND HMO OR SERVICE COMPANY SUBSIDIARIES OF THE CIGNA GROUP. © 2025 THE CIGNA GROUP.